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The Pain Clinic at Universitas Academic Hospital in Bloemfontein, 
South Africa (SA), sees patients with various forms of chronic pain, 
most commonly back pain. Treating patients with low back pain 
often includes exposure of the patient’s buttocks. Doctors in the 
clinic have occasionally noted disfiguring skin scars on the buttocks 
of patients that had developed after they had received intramuscular 
(IM) injections for their pain. These injections had been given 
elsewhere and were often reported by the patients to be IM diclofenac 
(Voltaren). It is not practice in this clinic to use or prescribe IM 
diclofenac. Some patients also reported that they had received IM 
diclofenac without a prescription, and that the injections had been 
administered by persons other than healthcare professionals.
IM diclofenac is on the South African Standard Treatment 
Guidelines and Essential Medicines List for treatment of adults with 
acute pain.[1] The current national contract for IM diclofenac in SA 
is for the period 1 June 2014 to 28 February 2017 and comprises 
~ 6.77 million ampoules of IM diclofenac. The Free State Province had 
an annual usage rate of 115 700 ampoules for the period 1 Decem­
ber 2014 ­ 30 November 2015, while usage at Universitas Academic 
Hospital was 1 910 ampoules between 1 July 2014 and 30 June 2015. [2] 
This information was confirmed by personal communication with 
the assistant manager, Pharmaceutical Services, Medpharm, Free 
State Department of Health (9 November 2015) and a pharmacist at 
Universitas Academic Hospital (9 July 2015).
The extensive use of IM diclofenac in SA, where it is the only 
parenteral non­steroidal anti­inflammatory drug (NSAID) widely 
used in public hospitals, contrasts with the situation in other 
countries, where its use has been limited because of the ulceration, 
scarring and tissue loss that can result following its administration.[3,4]
Objective
The objective of this questionnaire­based study was to determine: 
(i) the prevalence of skin scars due to IM diclofenac in our patient 
community; (ii) how patients had obtained IM diclofenac; and (iii) 
who had administered it to them.
Methods
A prospective descriptive study was performed using a questionnaire 
and clinical examination. The study protocol was approved by the 
Ethics Committee of the Faculty of Health Sciences, University of 
the Free State (ref. no. 173/2013). All patients who attended the Pain 
Clinic at Universitas Academic Hospital over a 9­month period 
(1 December 2013 ­ 31 August 2014) were included in the study. 
Patients who attended the clinic more than once during this period 
were included for their first visit only.
Informed consent was obtained from each patient. Consent 
documents and information forms were available in the three main 
languages of the region, namely English, Afrikaans and Sesotho. 
Each patient who attended clinic during the study period was asked 
by the admitting nurse if they had ever received an IM diclofenac 
or Voltaren injection. If they answered ‘yes’, they were asked to 
participate in the study. The nurse kept a record of how many patients 
seen at the clinic answered ‘yes’ or ‘no’.
Participants included in the study completed a questionnaire and 
underwent a non­invasive physical examination of the injection site 
by the doctor working in the clinic, who was either an anaesthetic 
consultant or a registrar. Information was collected confidentially. 
The folders were marked to ensure that each patient participated only 
once during the period of the study.
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On physical examination of the partici pant, 
the following information was recorded: 
body mass index (BMI) of the patient; site 
of the intramuscular injection(s); and skin 
changes at the injection sites, such as scarring, 
ulcer formation or changes suggestive of a 
healed ulcer. When a scar was observed, its 
size was measured and any changes in colour 
and/or sensation (increased or decreased 
sensation) associated with the scar were 
noted. A photograph of the scar was taken 
as documentation, with the patient’s consent.
A pilot study conducted on five patients 
during the month before the study period 
resulted in some items on the questionnaire 
being rephrased. The amendments to the 
questionnaire were approved by the Ethics 
Committee before commencement of the 
study. The results from the pilot study were 
not included in subsequent data analysis.
Statistical analysis
Data analysis was performed by the 
Department of Biostatistics, University of 
the Free State. Results were summarised 
by frequencies and percentages (categorical 
variables) and means and standard deviations 
(SDs) of percentiles (numerical variables).
Results
Two hundred and nineteen patients attend­
ed the Pain Clinic during the study peri­
od. When asked whether they had ever 
received a diclofenac or Voltaren injection, 
131 patients (59.8%) answered ‘yes’ and were 
asked to participate in the study.
The mean age of the participants was 
54.2 years (SD 12.1, range 23 ­ 80). The BMI 
was recorded in 127 participants, who had 
a median BMI of 29.2 kg/m2 (range 16.2  ­ 
56.6). Approximately two­thirds (66.4%) 
of the participants were female. Seventeen 
participants (13.0%) had diabetes mellitus. 
The median number of injections received 
by each participant was 8 (range 1 ­ 95).
One hundred and twenty­five participants 
(95.4%) stated in the questionnaire that the 
pain­relieving injection they had previously 
received had been diclofenac (Voltaren). 
The remaining 6 participants were unsure 
of the name of the drug injected (although 
they had initially said they thought they 
had received a diclofenac injection). Of the 
125  participants who stated that the injec­
tion had been diclofenac, 94.4% (n=118) 
were 100% sure of the name of the injection, 
4.0% (n=5) were 60 ­ 90% sure, and 1.6% 
(n=2) were less than 60% sure.
The data analysis was continued only 
for the 118 participants who indicated that 
they were 100% sure that the pain­relieving 
injection they had received had been diclo­
fenac. Ten (8.5%) of these participants were 
identified as having a scar, of whom 5 had a 
BMI >30 kg/m2. Of the patients with diabetes, 
18.8% had a scar, compared with 6.9% of 
patients without diabetes (p=0.14).
Of the 118 participants who were 100% 
sure that the pain­relieving injection had 
been diclofenac, 66 (55.9%) indicated that 
it had been administered by a general 
practitioner. Diclofenac injections had also 
been administered by a trained nurse (n=37, 
31.4%) and a pharmacist (n=29, 24.6%), and 
in 6 cases (5.1%) by a family member with 
medical training (Fig. 1). In 3 cases (2.5%) the 
diclofenac injection had been administered 
by a family member without medical training, 
and in 3 cases (2.5%) it was self­administered.
When asked where the IM diclofenac had 
been obtained from (Fig. 2), 51.7% (n=61) 
of the participants indicated it had been 
obtained from a general practitioner and 
37.3% (n=44) had obtained it from a private 
pharmacist. Other sources are also shown 
in Fig. 2.
In response to the question ‘If you 
received the injection from a pharmacist, 
did you have a prescription?’, 38 (66.7%) 
of the 57 participants who had obtained 
the diclofenac from either a private or a 
hospital pharmacy said that they had never 
had a prescription for it (Table 1); these 
38 participants lived a median of 3 km from 
a medical doctor (range 1 ­ 32 km). In res­
ponse to the question ‘Have you ever been 
warned that you may get a skin scar from 
IM diclofenac injection?’, 93 participants 
(78.8%) indicated that they had not been 
warned.
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Fig. 1. Participants’ responses to the questionnaire item ‘Who administered the pain-relieving injection?’ 
(More than one option could be chosen.)
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Fig. 2. Participants’ responses to the questionnaire item ‘Where did you obtain the pain-relieving injec-
tion?’ (More than one option could be chosen.)
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Most injections had been given recently, with 80 participants 
(67.8%) indicating that they had received their last IM diclofenac 
injection during the preceding year, 22 (18.6%) in the past 5 years 
and 16 (13.6%) >5 years previously. Of the 10 participants who had 
developed a scar from the diclofenac injection, 7 had received the 
injection within the preceding year, 1 within the preceding 5 years, 
and 2 >5 years previously.
As shown in Table 2, the most common complication noted after 
the diclofenac injection reported by participants who were 100% 
sure that they had received IM diclofenac was pain (n=27, 22.9%), 
followed by pruritus (n=23, 19.5%) and erythema (n=19, 16.1%) 
at the site of injection. Scarring at the injection site was initially 
reported by only 2 patients, although 10 patients were subsequently 
identified on the medical examination as having a scar.
Of the participants who could provide information regarding 
the site of injection, the majority indicated that the IM diclofenac 
had been administered into the buttocks (n=110, 93.2%). Other 
sites included the arm, thigh and shoulder, directly into the painful 
muscle, and the abdomen, knee and back, as shown in Table 3.
The patients with scars had received a median of 15 injections 
(range 2 ­ 95), compared with a median of 6 injections (range 1 ­ 50) 
for the patients without scars (p=0.08). Of the 10 participants who 
had scars associated with IM diclofenac injections (Table 4), all had 
scars on the buttocks and 2 also had scars on the upper arm (deltoid 
region). No scars were observed elsewhere. Three participants 
experienced ongoing hyperalgesia or allodynia over the site of the 
scars, and 2 had decreased sensation at the site of the scar. The size 
of the scars ranged from 5 × 5 mm2 to 30 × 40 mm2. Skin colour 
changes, observed in 4 participants, were described as either a blue 
discolouration or hyperpigmentation. Panels A, B and C in Fig. 3 
show examples of the skin lesions associated with IM diclofenac 
injections observed in the participants in the study. Two of the 10 
participants with confirmed scarring (Table 4) and needing medical 
attention had also required surgical treatment in the form of incision 
and drainage of an abscess.
Discussion
Diclofenac is an NSAID with analgesic, anti­inflammatory and 
antipyretic properties. NSAIDs are used to treat a wide spectrum of 
ailments including musculoskeletal or joint pain, soft­tissue injury, 
acute gout, renal colic and postoperative pain. Parenteral administration 
is favoured for acutely painful conditions, with the IM route often used 
as a stat injection. When given intravenously, diclofenac has to be given 
as a slow infusion, and thrombophlebitis may result.[5]
Skin complications from IM diclofenac have been reported 
previously. The findings of a 25­year analysis of complications due 
to IM diclofenac injections published in the BMJ in 2003[6] (response 
to Wright et al.[4]), reviewing the Novartis Global Safety Database 
of spontaneous and clinical trial reports for diclofenac ampoules 
from 1978 to 2003, revealed 115 reports of injection site necrosis, 
37  reports of site abscess, 11 reports of injection site reaction, 
6 reports of necrotising fasciitis and 2 cases of necrotising myositis. 
Pain on injection was only reported in 9 of these recorded cases.[6]
The review[6] compared these complications with the frequency 
that IM diclofenac was used. Over the 25­year period it was estimated 
that >100 million units of IM diclofenac were used (4 million per 
annum) in the UK. The incidence of lesions associated with IM 
Table 1. Responses to the questionnaire item on whether the 
participant had a prescription for IM diclofenac obtained 
from a pharmacist (N=57)
Prescription used n (%)
Never 38 (66.7)
Sometimes 9 (15.8)
Always 10 (17.5)
Table 2. Complications noted after administration of the IM 
diclofenac injection (N=118)
Complications* n (%)
Pain at injection site 27 (22.9)
Pruritus at injection site 23 (19.5)
Erythema at injection site 19 (16.1)
Ulceration/skin damage at injection site 3 (2.5)
Scarring at injection site 2 (1.7)
Nausea 1 (0.9)
No skin changes 65 (55.1)
*Participants could report more than one complication.
Fig. 3. Examples of skin scars associated with previous IM diclofenac injections in three patients. The black circles on the skin are the sites marked for trigger 
point injections. The more extensive scar seen in panel B resulted from abscess formation requiring surgical drainage.
A B C
Table 3. Sites of diclofenac injections (N=118)
Site* n (%)
Buttock 110 (93.2)
Arm 6 (5.1)
Thigh 6 (5.1)
Shoulder 2 (1.7)
Painful muscle 1 (0.8)
Abdomen 1 (0.8)
Knee 1 (0.8)
Back 1 (0.8)
*Participants could indicate more than one site.
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diclofenac could therefore be regarded as 
diminutive. The review[6] also reported that 
for 10 167 IM injections of diclofenac the 
incidence of abscess was 0.05%, necrosis 
at the injection site 0.02% and pain at the 
injection site 5.6%.
The results of the present study show a 
much higher risk of scars from IM diclo­
fenac injection, with an 8.5% prevalence 
of scarring. The markedly different results 
from the Novartis Database could indicate a 
considerable under­reporting of skin lesions 
resulting from diclofenac injections.
While skin scars can be unsightly or 
painful (30% of the scars in this study were 
associated with hyperalgesia or allodynia), 
the skin complications of IM diclofenac can 
have more serious results. A particularly 
severe skin complication of IM diclofenac is 
Nicolau syndrome (embolia cutis medica­
mentosa). This is a rare occurrence that 
has followed IM injections of diclofenac 
and other common drugs, including other 
NSAIDs, corticosteroids and penicillin. The 
clinical presentation is typically pain around 
the injection site, followed by erythema, 
liveoid patch, haemorrhagic patch and finally 
necrosis of the skin, subcutaneous fat and 
muscle tissue. Several case reports of Nicolau 
syndrome following intramuscular diclofenac 
have been published, with severe scarring and 
even death as an outcome.[6­8]
Nicolau syndrome was first described in 
1925 following the use of bismuth salts for 
the treatment of syphilis. This phenomenon 
has now been related to the administration 
of a variety of drugs such as corticosteroids, 
local anaesthetics and antihistamines.[7] The 
pathogenesis of Nicolau syndrome is not 
well understood, but probably involves acute 
vasospasm, arteritis and thromboembolic 
occlusion of small arteries resulting in 
end­organ damage. Diclofenac is associated 
with the vasoconstrictive phenomenon as 
it inhibits prostaglandin synthesis due to 
cyclo oxygenase inhibition, and can therefore 
cause Nicolau syndrome or milder forms of 
skin necrosis.[9]
The manufacturer’s instructions for IM 
diclofenac are very detailed and explicit, 
clearly stating that the injection should be 
administered by deep intragluteal injection 
(not in other sites such as the leg or arm), 
using strict aseptic techniques and not 
exceeding the recommended dose. It also 
states that subcutaneous and intravascular 
injection must be avoided to prevent skin 
scarring.[6,8] Furthermore, the Z­track meth­
od of IM injection, as described and illus­
trated by Lie et al.,[8] can minimise sub­
cutaneous irritation by blocking the needle 
track after injection and should be adopted 
as a standard procedure. According to this 
method, with the skin, subcutaneous fat and 
muscle in a normal position, the skin and 
subcutaneous layer should be pulled down 
1 cm to de­align with the underlying muscle. 
The needle should be inserted at 90o to 
administer the injection into the muscle and 
then withdrawn. When the finger is released 
to break the needle track, the drug is trapped 
inside the muscle.[8]
In SA, IM diclofenac is a schedule 3 drug 
and should only be dispensed to patients 
with chronic pain with a prescription by a 
medical doctor. However, diclofenac may 
be dispensed by a pharmacist without a 
prescription as a schedule 2 drug (Medicines 
and Related Substances Act 101 of 1965, 
Section 22A(5)(a)) for the emergency treat­
ment of acute gout and post­traumatic 
injuries for 5 days only.[10,11] IM diclofenac 
should only be administered by a trained 
health care professional. A pharmacist  may 
administer IM diclofenac if he or she has 
received the necessary training and is 
compe tent in the technique. Our findings 
show that IM diclofenac was inappropriately 
dispensed by some pharmacists, as two­
thirds of the patients who were dispensed 
IM diclofenac from a pharmacy received it 
without a prescription – a matter of concern, 
because it implies that some pharmacists 
dispense this drug illegally. This cannot be 
excused by claiming that these individuals 
were not able to visit a doctor to obtain a 
prescription for the injection because they 
lived in remote, rural areas, as they lived on 
average only a few kilometres away from a 
medical doctor.
This study did not investigate whether 
the participants who received the injection 
from a pharmacist received it from one 
trained in the correct technique. This may be 
investigated in a further study. A concerning 
finding was that several participants rec­
eived IM diclofenac injections from an 
unauthorised person or even administered 
the injection themselves. This suggests that 
when IM diclofenac is dispensed, there 
should be tighter regulations to ensure 
that the patient only receives the injection 
from an appropriately trained healthcare 
professional. Incorrect administration was 
confirmed by the observation that two of the 
scars from IM diclofenac were on the upper 
arms of the participants.
Before receiving IM diclofenac, patients 
should be warned of the potential for skin 
scarring, which is clearly stated in the 
package insert. The scars are probably more 
common than previously thought, as 8.5% 
of the participants in this study who had 
received IM diclofenac had scars from this 
injection. Despite this cautionary note, 78.8% 
of the study population indicated that they 
had never been warned about skin scarring as 
a potential side­effect. Medical professionals 
should warn patients against this side­effect 
when prescribing IM diclofenac, as there may 
be legal implications if scars develop.
The skin scars from IM diclofenac given at 
the correct intragluteal site may not be visible 
to the affected individual and therefore not 
necessarily of concern to them. Some people, 
however, do not wish to have scars on their 
buttocks for their own personal reasons, 
and patients should therefore be informed 
of the possible risk before IM diclofenac 
Table 4. Summary of the 10 participants who developed scars associated with  
IM diclofenac injections
Patient no. BMI (kg/m2)
Diabetes 
mellitus Injection site
Injection site 
complications
Treatment 
required
1 26.9 No Buttock Erythema, 
abscess
Medical; 
incision and 
drainage
2 25.7 No Buttock, 
deltoid
Pain, scarring, 
pruritus, ulcer
­
3 29.8 No Buttock Pain, pruritus ­
4 25.0 No Buttock Pain, pruritus ­
5 33.8 Yes Buttock Pruritus ­
6 29.4 No Buttock Pruritus, ulcer Medical
7 37.2 Yes Buttock ­ ­
8 34.3 No Buttock, 
deltoid
Pain, abscess Incision and 
drainage
9 37.6 No Buttock Pain, erythema, 
pruritus
­
10 32.3 Yes Buttock None Medical
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is prescribed. In this study, some scars were large and some were 
chronically painful, demonstrating that there is notable morbidity 
associated with these scars.
Patients with diabetes are at risk of developing infections after 
any invasive procedure, and an infected IM diclofenac injection site 
increases the risk of scar formation. We suggest that diabetes mellitus 
should be considered a risk factor for developing scars from IM 
diclofenac. The prevalence of skin scars in diabetic participants was 
more than double that in non­diabetics, although the difference was 
not statistically significant. A larger study is necessary to determine 
the role of diabetes as a risk factor.
Study limitations
A major limitation of this study is that it relied on the memory of 
the participants completing the questionnaire. Recall bias may have 
exaggerated symptoms. They may not accurately have recalled all the IM 
diclofenac injections they had received in the past, or other related facts, 
or may have had an injection with another medication and erroneously 
said that it was diclofenac. Some participants did not answer all the 
questions, and data were lost in this small number of cases.
Conclusions
A larger prospective study to investigate the risk of skin scars from 
IM diclofenac injections is required. Until this has been done, 
patients should be warned that they may develop a skin scar after 
IM diclofenac, as stated in the package insert. This warning should 
be documented as having been given, and oral diclofenac should be 
prescribed where possible.
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